The FDA launched the Coronavirus Treatment Acceleration Program (CTAP), an emergency program for potential COVID-19 therapies.

The agency has deployed staff specifically to reviewing COVID-19 therapies.

The agency is currently monitoring 10 therapies in active trials and 15 others in planning stages.